IDXX shows strong CAG Diagnostics growth, cloud software momentum and global expansion but faces solvency and macro risks.

Idexx (IDXX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Major U.S. equities indexes pushed higher at the top of the new trading week, bouncing back from declines posted ahead of the weekend. Although weaker-than-expected jobs data released on Friday rai...

IDEXX Laboratories, Inc. (NASDAQ:IDXX ) Q2 2025 Earnings Conference Call August 4, 2025 8:30 AM ET Company Participants Andrew Emerson - Executive VP, CFO & Treasurer Jonathan J. Mazelsky - Preside...

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced second quarter results. “Our innovation-driven strategy del...

I rate IDEXX Laboratories a buy, driven by a lasting surge in pet ownership and IDXX's leadership in veterinary diagnostics. New platforms like inVue Dx and Cancer Dx provide additional growth driv...

Shares of IDEXX Laboratories (IDXX) surged 10% to lead S&P 500 gainers Monday after the provider of veterinary healthcare products and services reported better-than-anticipated results on demand fo...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

IDEXX's robust strength in the CAG Diagnostics business and strong global performance are highly promising.

I reiterate a 'Sell' rating on IDEXX due to weak U.S. clinical visits and demand, with a one-year price target of $400 per share. IDEXX's Q3 results showed a 2.1% decline in same-store clinical vis...

IDXX's Q3 revenues benefit from strong growth in its CAG and Water segments.

Evaluate the expected performance of Idexx (IDXX) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metri...

IDEXX Laboratories' third-quarter 2024 performance is expected to have benefited from a strong execution against strategic priorities.

IDEXX reported lower full-year organic revenue growth due to reduced U.S. clinical visits. Weak consumer sentiment and ongoing staffing challenges may continue to impact clinical visits in the near...